Researchers have identified the earliest signs of Parkinson’s disease in the brain, many years before patients show any symptoms.
A recent study in mice has identified a chemical substance, OB-1, which dampens the perception of light touch and could be used to target neuropathic pain.
This study suggests that correct use of cognitive screening instruments may conveivably help to narrow the ‘dementia diagnosis gap’.
The underexpression of the microRNA, termed miR-9, has been linked to the development of schizophrenia in a small subset of patients.
Part 2 of our first ‘Ask the experts’ focuses down on the screening debate, discussing the arguments for and against screening and the ethical considerations.
This opinion piece discusses the issues with identification and management of depression in brain tumor patients and recommends best practice within the field.